Claudin14 Promotes Colorectal Cancer Progression Via the PI3K/AKT/mTOR Pathway
Authors
Affiliations
Colorectal cancer is the third leading cancer in the world in terms of incidence and mortality. The role of differentially expressed Claudin-14 (CLDN14) in CRC has not been reported. We observed that CLDN14 was associated with the progression of CRC. Our functional studies have shown that CLDN14 promoted the proliferation of CRC cells. In addition, CLDN14 also increased the migration and invasion of CRC cells. In vivo experiments also showed that CLDN14 promoted the growth of colorectal cancer via the PI3K/AKT/mTOR. In summary, our research suggests that CLDN14 promotes the progression of colorectal cancer. Our findings may provide new strategies for clinical management and patient prognosis of CRC.
Anti-tumor potential of high salt in breast Cancer cell lines.
Sharma M, Dey U, Das A, Olymon K, Kumar A, Mukhopadhyay R Mol Biol Rep. 2024; 51(1):1002.
PMID: 39305332 DOI: 10.1007/s11033-024-09925-4.
Dual PI3K/mTOR Inhibitor BEZ235 combined with BMS-1166 Promoting Apoptosis in Colorectal Cancer.
Liu X, Xu W, Li L, Zhang Z, Lu M, Xia X Int J Med Sci. 2024; 21(10):1814-1823.
PMID: 39113885 PMC: 11302559. DOI: 10.7150/ijms.84320.
The Expression of the Claudin Family of Proteins in Colorectal Cancer.
Cox K, Liu S, Hoffman R, Batra S, Dhawan P, Bouvet M Biomolecules. 2024; 14(3).
PMID: 38540693 PMC: 10967842. DOI: 10.3390/biom14030272.
Expression patterns of claudins in cancer.
Tao D, Guan B, Li H, Zhou C Heliyon. 2023; 9(11):e21338.
PMID: 37954388 PMC: 10637965. DOI: 10.1016/j.heliyon.2023.e21338.
Alghamdi R, Al-Zahrani M Front Genet. 2023; 14:1221815.
PMID: 37799140 PMC: 10550083. DOI: 10.3389/fgene.2023.1221815.